iifl-logo-icon 1

Zydus Lifesciences Ltd Nine Monthly Results

1,154.55
(0.88%)
Jul 22, 2024|03:32:43 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Dec-2023Dec-2022Dec-2021Dec-2020Dec-2019

Gross Sales

13,655.1

12,025.3

11,148.8

10,616.8

10,184.9

Excise Duty

0

0

0

0

0

Net Sales

13,655.1

12,025.3

11,148.8

10,616.8

10,184.9

Other Operating Income

358.5

544.4

316.4

189.7

316.1

Other Income

147.5

148.8

2,664.2

153.5

69.6

Total Income

14,161.1

12,718.5

14,129.4

10,960

10,570.6

Total Expenditure

10,274

9,970.7

9,014.6

8,567.7

8,819.9

PBIDT

3,887.1

2,747.8

5,114.8

2,392.3

1,750.7

Interest

46.6

102.2

88.5

140

259.3

PBDT

3,840.5

2,645.6

5,026.3

2,252.3

1,491.4

Depreciation

558.8

544.1

550.7

523.6

518

Minority Interest Before NP

0

0

0

0

0

Tax

1,027.7

460.6

323.8

338.1

187.3

Deferred Tax

-371.4

-10

28.4

-15.4

24

Reported Profit After Tax

2,625.4

1,650.9

4,123.4

1,406

762.1

Minority Interest After NP

49.5

70

75.1

-5

6

Net Profit after Minority Interest

2,677.2

1,663.7

4,089.9

1,454.6

784.7

Extra-ordinary Items

1.13

-4.67

2,405.58

-104.99

-243.49

Adjusted Profit After Extra-ordinary item

2,676.07

1,668.37

1,684.32

1,559.59

1,028.19

EPS (Unit Curr.)

26.45

16.33

39.95

14.21

7.67

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

101.2

101.2

102.4

102.4

102.4

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

28.46

22.85

45.87

22.53

17.18

PBDTM(%)

28.12

22

45.08

21.21

14.64

PATM(%)

19.22

13.72

36.98

13.24

7.48

Zydus Lifesci.: Related NEWS

Zydus Lifesciences Shares Drop 3% as USFDA Issues OAI Status to Facility
19 Jul 2024|03:00 PM

The OAI classification is the most severe of the three possible classifications assigned by the US FDA

Read More
Zydus Lifesciences’s Gujarat facility gets OAI classification
19 Jul 2024|12:40 PM

Following this development, company’s counter slipped nearly 3% to an intraday low of ₹1,150.05 per piece on NSE.

Read More
Top 10 stocks for today – 19th July, 2024
19 Jul 2024|08:46 AM

Here are some of the stocks that may see significant price movement today: Infosys, Tata Technologies, L&T Technology Services, etc.

Read More
Zydus Lifesciences gains FDA nod for MS and heart failure treatments
11 Jul 2024|12:48 PM

Notably, diroximel fumarate delayed-release capsules have garnered substantial traction in the U.S. market, generating annual sales of $5,483 million by May 2024 (IQVIA MAT).

Read More
Top 10 stocks for today – 11th July 2024
11 Jul 2024|08:38 AM

Here are some of the stocks that may see significant price movement today: SBI, Sula Vineyards, Zydus Lifesciences, Kesoram Industries, etc.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.